BRPI0507342A - sólidos supersaturados estabilizados de fármacos lipofìlicos - Google Patents
sólidos supersaturados estabilizados de fármacos lipofìlicosInfo
- Publication number
- BRPI0507342A BRPI0507342A BRPI0507342-1A BRPI0507342A BRPI0507342A BR PI0507342 A BRPI0507342 A BR PI0507342A BR PI0507342 A BRPI0507342 A BR PI0507342A BR PI0507342 A BRPI0507342 A BR PI0507342A
- Authority
- BR
- Brazil
- Prior art keywords
- lipophilic
- drugs
- solids
- lipophilic drugs
- stabilized
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 239000007787 solid Substances 0.000 title abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- -1 for example Chemical compound 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55133004P | 2004-03-10 | 2004-03-10 | |
| EP04075714 | 2004-03-10 | ||
| PCT/IB2005/000748 WO2005087199A2 (en) | 2004-03-10 | 2005-03-10 | Stabilised supersaturated solid solutions of steroidal drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507342A true BRPI0507342A (pt) | 2007-07-03 |
Family
ID=34928105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507342-1A BRPI0507342A (pt) | 2004-03-10 | 2005-03-10 | sólidos supersaturados estabilizados de fármacos lipofìlicos |
Country Status (32)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008127609A1 (en) * | 2007-04-11 | 2008-10-23 | Mccarty John A | Melatonin tablet and methods of preparation and use |
| US10172810B2 (en) | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
| CA2612456C (en) * | 2005-06-16 | 2017-06-06 | Warner Chilcott Company, Inc. | Gel compositions for topical administration |
| WO2006138686A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
| WO2007128350A1 (en) * | 2006-05-10 | 2007-11-15 | Evonik Degussa Gmbh | Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions |
| LT2487163T (lt) | 2007-02-23 | 2016-10-25 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| US20110097405A1 (en) * | 2008-02-13 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Estradiol-containing drug delivery system |
| WO2009113522A1 (ja) * | 2008-03-11 | 2009-09-17 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
| BRPI0911871A8 (pt) | 2008-05-02 | 2018-03-06 | Gilead Sciences Inc | uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico |
| WO2009138224A1 (en) * | 2008-05-14 | 2009-11-19 | Helm Ag | Pharmaceutical composition comprising drospirenone |
| EP2381946A4 (en) * | 2008-10-10 | 2012-08-08 | Teva Womens Health Inc | METHOD FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN CASE RATED PROSTATE RAY PATIENTS WITH LOW-DOSED CYPROTERONE ACETATE |
| WO2010094623A1 (en) * | 2009-02-18 | 2010-08-26 | Bayer Schering Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
| US9005608B2 (en) * | 2009-03-24 | 2015-04-14 | Adds Pharmaceuticals Llc | Stabilized solubility-enhanced formulations for oral delivery |
| FR2947178B1 (fr) * | 2009-06-29 | 2012-07-06 | Effik | Composition pharmaceutique a base de progesterone micronisee et ses utilisations |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| WO2012120365A1 (en) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Stable pharmaceutical composition comprising ethinyl estradiol |
| US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20140303128A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3171871B1 (en) | 2014-07-21 | 2024-10-23 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal or sublingual administration of cannabinoids |
| AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| CN106109420B (zh) * | 2016-08-11 | 2018-07-06 | 吴启旸 | 依普利酮固体分散体及其制剂 |
| US11013245B2 (en) * | 2017-02-14 | 2021-05-25 | Dsm Ip Assets B.V. | Water dispersible formulations |
| US10806706B2 (en) * | 2017-02-14 | 2020-10-20 | Dsm Ip Assets B.V. | Storage-stable formulations |
| CN110013467B (zh) * | 2018-01-10 | 2021-09-17 | 上海汉都医药科技有限公司 | 一种固体微粒及其制备方法和含其的药物组合物 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| JP2022069437A (ja) * | 2020-10-23 | 2022-05-11 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA72698B (en) * | 1972-02-03 | 1973-09-26 | Liebenberg R W | Method of preparing medicinal compositions |
| US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| GB8403359D0 (en) | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
| IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
| DE3916112A1 (de) | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
| ATE102022T1 (de) | 1990-08-30 | 1994-03-15 | Senju Pharma Co | Zusammensetzung zur kontrollierten abgabe von medikamenten. |
| ATE118178T1 (de) * | 1990-11-29 | 1995-02-15 | Faulding F H & Co Ltd | Verfahren zur herstellung von flüssigkeiten enthaltenden pulvern. |
| DE4326240A1 (de) | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
| US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US5789442A (en) | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| US5800834A (en) | 1996-06-10 | 1998-09-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
| US6027747A (en) | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
| KR20000000016A (ko) | 1999-02-10 | 2000-01-15 | 김일 | 자동차용번호판부착볼트구조 |
| EP1598069B1 (en) | 1999-08-31 | 2009-04-22 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| BR0107683A (pt) | 2000-01-18 | 2002-11-12 | Schering Ag | Drospirenona para terapia de reposição de hormÈnio |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| CA2448825C (en) * | 2001-06-22 | 2009-08-11 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drug |
| ITMC20010031U1 (it) | 2001-07-05 | 2003-01-07 | Best Raffaello Srl | Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo |
| SE0103838D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| EP1551415B1 (en) | 2002-09-05 | 2009-12-23 | Pantarhei Bioscience B.V. | Oral pharmaceutical composition comprising 15-hydroxytestosterone and its analogues |
| DK1558265T3 (da) | 2002-11-05 | 2010-03-15 | Bayer Schering Pharma Ag | Anvendelse af dropspirenon til behandling af hypertension |
| DE20217332U1 (de) | 2002-11-11 | 2003-02-27 | Brand Factory Swiss Gmbh, Rotkreuz | Socke |
| WO2004073689A1 (en) | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
| FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
| DE602005014227D1 (de) | 2004-03-10 | 2009-06-10 | Bayer Schering Pharma Ag | Zusammensetzungen aus drospirenon in molekularer dispersion |
-
2005
- 2005-03-09 MY MYPI20050963A patent/MY142989A/en unknown
- 2005-03-10 PL PL05718248T patent/PL1765290T3/pl unknown
- 2005-03-10 JP JP2007502437A patent/JP5006185B2/ja not_active Expired - Fee Related
- 2005-03-10 ES ES05718248T patent/ES2332229T3/es not_active Expired - Lifetime
- 2005-03-10 UY UY28803A patent/UY28803A1/es not_active Application Discontinuation
- 2005-03-10 AT AT05718248T patent/ATE442131T1/de active
- 2005-03-10 WO PCT/IB2005/000748 patent/WO2005087199A2/en not_active Ceased
- 2005-03-10 ES ES09161378T patent/ES2390406T3/es not_active Expired - Lifetime
- 2005-03-10 EP EP09161378A patent/EP2087883B1/en not_active Expired - Lifetime
- 2005-03-10 HR HR20090614T patent/HRP20090614T1/hr unknown
- 2005-03-10 SI SI200530840T patent/SI1765290T1/sl unknown
- 2005-03-10 US US11/076,022 patent/US8715735B2/en not_active Expired - Fee Related
- 2005-03-10 DK DK05718248T patent/DK1765290T3/da active
- 2005-03-10 CN CN2005800150633A patent/CN1984644B/zh not_active Expired - Fee Related
- 2005-03-10 AR ARP050100924A patent/AR048500A1/es not_active Application Discontinuation
- 2005-03-10 EP EP05718248A patent/EP1765290B1/en not_active Expired - Lifetime
- 2005-03-10 BR BRPI0507342-1A patent/BRPI0507342A/pt not_active IP Right Cessation
- 2005-03-10 EA EA200601588A patent/EA012746B1/ru not_active IP Right Cessation
- 2005-03-10 AU AU2005221403A patent/AU2005221403B8/en not_active Ceased
- 2005-03-10 GT GT200500045A patent/GT200500045A/es unknown
- 2005-03-10 CA CA2558582A patent/CA2558582C/en not_active Expired - Fee Related
- 2005-03-10 SV SV2005002044A patent/SV2005002044A/es unknown
- 2005-03-10 TW TW094107345A patent/TWI345986B/zh not_active IP Right Cessation
- 2005-03-10 DE DE602005016551T patent/DE602005016551D1/de not_active Expired - Lifetime
- 2005-03-10 PA PA20058626101A patent/PA8626101A1/es unknown
- 2005-03-10 PT PT05718248T patent/PT1765290E/pt unknown
- 2005-03-10 RS RSP-2009/0508A patent/RS51076B/sr unknown
- 2005-03-10 NZ NZ549793A patent/NZ549793A/en unknown
- 2005-03-10 PE PE2005000277A patent/PE20060016A1/es not_active Application Discontinuation
-
2006
- 2006-09-05 IL IL177894A patent/IL177894A0/en unknown
- 2006-09-14 CR CR8630A patent/CR8630A/es unknown
- 2006-10-02 EC EC2006006902A patent/ECSP066902A/es unknown
- 2006-10-02 NO NO20064473A patent/NO20064473L/no not_active Application Discontinuation
- 2006-10-09 KR KR1020067020937A patent/KR101210695B1/ko not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507342A (pt) | sólidos supersaturados estabilizados de fármacos lipofìlicos | |
| FR24C1014I1 (fr) | Derives benzonitrile substitues par le glucopyranosyle, compositions pharmaceutiques les contenant et utilisation et preparation de tels composes | |
| BR0211736A (pt) | Formulação para suspensão oral estabilizada | |
| BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
| BR0215380A (pt) | Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo | |
| ES2195308T3 (es) | Composicon farmaceutica de fenofibrato que presenta una biodisponibilidad elevada, y metodo para su preparacion. | |
| BR0107445A (pt) | Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco | |
| EA200601570A1 (ru) | Композиции, содержащие молекулярно диспергированный дроспиренон | |
| BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
| BRPI0815079A2 (pt) | Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto | |
| GT200600194A (es) | Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada | |
| BR9914932A (pt) | Processo para a manufatura de uma composição de isotretinoìna, composição de isotretinoìna micronizada, forma de dosagem unitária para administração enteral e composição farmacêutica na forma de dosagem unitária | |
| BR9910481A (pt) | Composição farmacêutica para comprimido de liberação não-contìnua | |
| BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
| FR2909284B1 (fr) | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien | |
| BRPI0518191A (pt) | métodos e composições para reduzir a toxicidade de um composto farmacêutico | |
| BR0116179A (pt) | Composição despejável, processo de preparação de uma composição despejável e uso da composição | |
| SI1475379T1 (sl) | Uporaba derivatov skopinskega estra za pripravo zdravil | |
| BRPI0603197A (pt) | composição de toner | |
| ECSP055998A (es) | Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético | |
| GT200500122A (es) | Profarmacos de esteroides con accion androgenica | |
| WO2001022943A8 (en) | A slow release pharmaceutical composition comprising a magnesium oxychloride cement | |
| GT200500120A (es) | Prodrogas de estriol y estetrol | |
| DE60121293D1 (de) | Pharmazeutische zusammensetzungen, welche steroidische strukturen enthalten, und deren verwendungen | |
| PE20070529A1 (es) | Composicion farmaceutica que contiene azodicarbonamida micronizada y su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) Free format text: NOME ALTERADO DE: SCHERING AKTIENGESELLSCHAFT |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE, CONFORME ART. 10 DA RES. 124/06. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |